
UnitedHealth Group (UNH) received a 77% rating from Validea's P/B Growth Investor model, based on Partha Mohanram's academic strategy designed to identify outperforming growth stocks. While this score is just below the 80% threshold for strategic interest, UNH passed most fundamental growth criteria, including profitability and cash flow metrics, suggesting it possesses strong characteristics for sustained future growth despite failing on advertising and R&D asset ratios.
UnitedHealth Group (UNH) scores a 77% rating according to Validea's P/B Growth Investor model, a framework developed by academic Partha Mohanram to identify high-quality growth stocks among low book-to-market companies. This score positions UNH just below the 80% threshold that indicates strategic interest from the model. The company demonstrates strong underlying fundamentals, passing crucial tests for book-to-market ratio, return on assets (ROA), cash flow from operations to assets, and the stability of its ROA and sales variance. These passes suggest robust profitability, efficient cash generation, and predictable performance. However, the model flagged failures on two criteria: advertising-to-assets and research and development-to-assets ratios. These weaknesses suggest that relative to its significant asset base, UNH's investment in traditional growth drivers like advertising and R&D is low, which prevents it from achieving a top-tier score within this specific growth-focused framework.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment